Funding domestic vaccine candidates as part of the Government of Canada's COVID‑­19 response

 

- Ottawa,

On October 23, 2020, the Prime Minister announced an investment of over $23 million through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support Canadian companies responding to COVID‑19.

NRC IRAP is providing advisory services and research and development funding to 6 Canadian companies for their COVID‑19 vaccine candidates, including:

  • Immunovaccine Technologies Inc. (Dartmouth, N.S.)
  • Entos Pharmaceuticals (Edmonton, Alta.)
  • Providence Therapeutics COVID Inc. (Toronto, Ont.)
  • Glycovax Pharma (Montreal, Que.)
  • Symvivo (Burnaby, B.C.)
  • Biodextris Inc. (Laval, Que.)

The support from NRC IRAP will help these companies advance their R&D efforts, and progress the vaccine candidates in different stages of clinical trials, helping Canadian industry compete in the very competitive global race to develop a COVID‑19 vaccine.

At this time, there are no vaccines authorized for the prevention of COVID‑19, but there are many in clinical trials or in development. For each candidate vaccine, once additional studies have been completed, Health Canada will review evidence of safety, efficacy and manufacturing quality to make a decision on whether the individual vaccines will be approved for use in Canada.